<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A phase II clinical trial on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> was conducted in a cooperative study with orally administrable ara-C analogue, PLAC, which is resistant to <z:chebi fb="0" ids="17562">cytidine</z:chebi> deaminase and had shown an anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> activity on various <z:e sem="disease" ids="C0027659" disease_type="Neoplastic Process;Experimental Model of Disease" abbrv="">experimental tumors</z:e> by oral route </plain></SENT>
<SENT sid="1" pm="."><plain>Fifty <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (3 RA, 18 RAEB, 11 RAEB-T, 18 RAEB-<z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> (BC) were treated orally with 100 to 400mg/body of daily PLAC </plain></SENT>
<SENT sid="2" pm="."><plain>One good response (GR) and 3 partial responses (PR) were obtained in 18 RAEB, and 2 complete remissions, 1 GR and 1 PR were noted in 11 RAEB-T, while 3 PR were seen in 18 RAEB-BC </plain></SENT>
<SENT sid="3" pm="."><plain>Overall CR rates were 4%, GR rates 4% and PR rates 14% </plain></SENT>
<SENT sid="4" pm="."><plain>Thus, 22% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> responded to oral PLAC </plain></SENT>
<SENT sid="5" pm="."><plain>No clear daily dose-response was noted </plain></SENT>
<SENT sid="6" pm="."><plain>Response, however, was dependent on the treatment period and was obtained in cases which had been treated for more than 20 days </plain></SENT>
<SENT sid="7" pm="."><plain>Besides <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e>, side effects were mainly gastrointestinal, and <z:hpo ids='HP_0002039'>anorexia</z:hpo> (32%), <z:hpo ids='HP_0002018'>nausea</z:hpo>/<z:hpo ids='HP_0002013'>vomiting</z:hpo> (30%) and <z:hpo ids='HP_0002014'>diarrhea</z:hpo> (8%) were observed </plain></SENT>
<SENT sid="8" pm="."><plain>Oral PLAC seems to be active on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> which does not necessarily require admission to hospital </plain></SENT>
</text></document>